Scientific advisory board
Dr. Robert Leo Murphy
Dr. Jonathan Bernstein
Dr. Julian Gordon
Dr. James Koziarz
Dr. David Kelso
Paul Detjen MD
Priya Bansal MD
Rob Murphy, MD is Professor of Medicine and Biomedical Engineering at Northwestern University where he is Executive Director, Institute for Global Health and John P. Phair Professor of Infectious Diseases. Dr. Murphy's primary research and clinical interest is in viral infections. His research focus includes drug development of new antiretroviral drugs and vaccines for HIV, other viruses and the scale-up of therapy for AIDS and its complications including tuberculosis and cancer in sub-Saharan Africa. Dr. Murphy was Country Director for the Harvard President's Emergency Plan for AIDS Relief (PEPFAR) program at its inception in 2004 which went on to treat over 150,000 persons living with HIV. He is Principal Investigator for NIH-supported research and research training grants in Africa involving HIV-related malignancies and tuberculosis. During the West African Ebola outbreak, he was the scientific director of the laboratory at the University of Bamako in Mali where confirmatory molecular testing for Ebola was performed. He is a member of the Newborn Essential Solutions and Technologies (NEST) team supported by the MacArthur Foundation, which aims to reduce neonatal mortality in Africa by 50%. He leads several NIH-supported cooperative agreements including one studying the epigenomics of HIV-related cancers in Nigeria and another developing point-of-care devices and assays that can be used to treat, monitor or prevent HIV-associated conditions in Africa. This grant recently pivoted its research focus to developing innovative diagnostic assays and devices for SARS-CoV-2 in a $1.5 billion program referred to as the Rapid Acceleration of Diagnostics for Coronavirus-19, RADx; he sits on the RADx Steering Panel and Clinical Review Board. Dr. Murphy has developed many antiviral drugs for HIV, viral hepatitis and now Coronavirus-19 and through these efforts was Medical Director or key advisor to several biotech companies including Idenix, Pharmasset, InnaVirVax, Diaccurate, Viriom and Atea Pharmaceuticals. Atea is currently developing AT-527, a promising oral drug that is being tested for SARS-CoV-2 infection. He is a founding board member of the Northwestern Global Health Foundation and faculty director of the online Master of Science in Global Health graduate degree program through the School of Professional Studies at Northwestern.
Dr. Priya Bansal attended a six-year BS/MD program with Penn State University and Thomas Jefferson Medical School. She completed her residency in Internal Medicine and Pediatrics at University of Illinois in Chicago and was board certified in both specialties. She then became board certified in Allergy and Immunology after her fellowship at Rush University Medical Center. Dr. Bansal served as President for the Illinois Society of Allergy and is currently a RSLAAIS governor for the American Academy of Allergy, Asthma, and Immunology (AAAAI). Dr. Bansal joined the AirAnswers® team to continue her mission of aiding in the alleviation of suffering for children and adults with allergies and asthma. "As a doctor and a mom of two children with food allergies, I could not be more excited about the incredible difference we are making in the lives of our clients," Dr. Bansal explains.
Ask a Chicago North Shore mom for an allergist, and she's very likely to refer you to Dr. Paul Detjen. He has been a practicing allergist-immunologist for over 20 years after receiving his medical degree from Washington University School of Medicine in St. Louis and completing his residency and fellowship at Northwestern University Feinberg School of Medicine. Dr. Detjen is affiliated with multiple hospitals in the Chicagoland area, including NorthShore Evanston Hospital and Northwestern Memorial Hospital. He has helped thousands of families address allergies and asthma to live healthier, better lives. Dr. Detjen believes in AirAnswers® – the product and the passionate team behind it. "I'm so thrilled that there's finally a science-based solution for detecting allergens that trigger allergies and asthma," Dr. Detjen says. "I know how stressful it is when your child can't breathe easily. That's why I am excited to be professionally involved with AirAnswers®."
Jonathan has 29 years of experience as a board certified and recertified allergist with over 285 publications related to areas of his expertise. A Professor of Clinical Medicine at the University of Cincinnati and a partner of Bernstein Allergy Group and Bernstein Clinical Research Center. His area of expertise is treatment of severe disease including asthma, difficult to treat chronic rhinitis, recurrent sinusitis with or without polyps, urticaria, angioedema including hereditary and acquired forms, atopic and contact dermatitis and other skin eruptions, food allergy including food challenges and oral immunotherapy, drug allergy including challenges and desensitizations, immunodeficiency (which may include neuropsychiatric disorders such as idiopathic autoimmune encephalopathy aka PANDAS/PANS), mast cell disorders with or without dysautonomia, eosinophilia disorders, environmental disorders including mold-related illnesses, women's health issues including progesterone hypersensitivity, seminal plasma hypersensitivity and chronic vulvovaginal candida hypersensitivity, idiopathic anaphylaxis and other complex unexplained disorders. His practice is a referral center for patients around the country.
"David has built and scaled multiple healthcare companies that resulted in the successful growth of his companies which leading to exits to strategic buyers. As a member of Inspirotec's Scientific and Strategic Advisory Board, David's extensive experiences and successful U.S. launch of new innovative products in the allergen & allergy testing and laboratory services will help drive Inspirotec's AirAnswers® patented air allergen devise, testing business, and consult services into its next growth phase. Recent past successes include CEO: Armune BioScience (sold to Exact Sciences [EXAS] Dec.2017) and US President: Phadia US/AB which launched and grew Immunocap™ blood allergen testing companyImmunoCAP® Specific IgE Blood Test (sold to Thermo Fisher Scientific [TMO] for $3.5 billion Sept. 2011)."
David Kelso is the distinguished Northwestern University Professor, Biomedical Engineering, McCormick School of Engineering and Applied Science; and a Director, Center for Innovation in Global Health Technologies (CIGHT). David has been a deep and extensive history in the fields of analytical instrumentation; medical devices, biosensors; kinetics of antibody and DNA binding reactions in solution and on solid phases. Before joining Northwestern, Professor Kelso developed a number of medical devices for the healthcare industry including Pandex founder, Chief Scientist at Baxter, and within intrapreneurial group Abbott Laboratories.
Dr. Koziarz was President and CEO of Rubicon Genomics, a leader in the commercialization of preanalytical processes to improve the performance and capabilities of analytical platforms for research and clinical testing. The company was sold to Takara Bio in 2017. Previously he worked for 25 years in the Diagnostics Division of Abbott Laboratories, including 11 years as a corporate officer where he managed groups involved in product development, manufacturing and customer technical support, and new technology management. Since retirement from Abbott, he has been an active member of the entrepreneurial and venture communities, serving as an advisor to PhysIQ and several early stage, venture-backed life sciences companies. Prior to joining Abbott in 1979, Jim was a postdoctoral fellow in biochemistry at the University of Chicago. He earned a B.S. in chemistry from DePaul University, a PhD in biochemistry from the University of Chicago and won a National Research Service Award as a postdoctoral fellow.
Julian is a world renowned serial inventor who has made groundbreaking contributions to multiple fields of science. His group at Abbott Labs was responsible for developing lateral flow immunoassay technology, which led to the first home pregnancy tests. Prior to Abbott Labs, Julian's group at Novartis (then CIBA-GEIGY) was responsible for inventing the Western Blot, an important method used today in molecular biology, biochemistry and immunogenetics for the characterization and detection of proteins. As a scientist, Julian is passionate about using evidence-based data to prevent human suffering. As he explains, "I know of no greater suffering than a mother in anguish about her child not being able to breathe normally – and not knowing what to do about it. I feel so fortunate to be part of an incredible team working to solve this problem".